AzTrials
AzTrials

Crohn DiseaseCALYPSONCT04102163

Health-Related Quality of Life in Crohn's Disease Participants With Complex Perianal Fistula Before and After Treatment

An observational study of Crohn Disease and Inflammatory Bowel Disease, run by Takeda at 20 sites in Spain.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The purpose of this study is to assess the impact of treatment (medical and/or surgical) on Health-related Quality of Life (HRQoL) in participants with Crohn's Disease (CD) and Complex Perianal Fistula (CPF), by the Quality of Life in patients with Anal Fistula Questionnaire (QoLAF-Q), at 12 months after treatment… Read more about this study

Who is it for?
Ages 18 years and older
How many people
19 participants
Where
20 sitesSpain
Study dates
26 Jan 2021to 26 May 2021
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Participants diagnosed with CD and CPF, who will initiate medical or surgical treatment for their CPF within Sep 2020 to Sep 2021, will be observed prospectively.

Who may be able to join

  • Diagnosed with CD and CPF (defined as a fistula meeting any of the following criteria: high location [high intersphincteric, high transsphincteric, extrasphincteric, or suprasphincteric], multiple external openings, perianal abscess, anal stenosis, or proctitis).
  • Has tried and failed at least one prior treatment for CPF.
  • Starting a new pharmacological or surgical treatment for CPF.

Who cannot join

  • Diagnosed with indeterminate/unspecified type of inflammatory bowel disease (IBD).
  • Diagnosed with ulcerative colitis.
  • Diagnosed with fistula other than CPF (example rectovaginal).
  • Treated with darvadstrocel or other stem cells-based therapies within the eligibility period.
  • Previous fecal incontinence.
  • Lost to site follow-up for reasons other than death.
  • Participates or plans to participate in any interventional clinical trial.
  • Non fluent in Spanish.

Trial locations and contacts

20 sites in 1 country.

20 sites in 1 country

Spain20 sites
  • Complejo Hospitalario Universitario de Ferrol

    A Coruña, Galicia, 15405

  • Hospital Santa creu i Sant Pau

    Barcelona, Catalonia, 08025

  • Hospital Universitario Vall d'Hebron

    Barcelona, Catalonia, 08035

  • Hospital Parc Tauli

    Barcelona, Catalonia, 08208

  • Hospital Reina Sofia

    Córdoba, Andalusia, 14004

  • Hospital de Fuenlabrada

    Fuenlabrada, Madrid, 28942

  • Hospital San Cecilio

    Granada, Andalusia, 18016

  • Hospital Universiario Juan Ramon Jimenez

    Huelva, Andalusia, 21005

  • Hospital Universitario de Bellvitge

    L'Hospitalet de Llobregat, Catalonia, 08907

  • Hospital La Princesa

    Madrid, Madrid, 28006

  • Hospital Gregorio Maranon

    Madrid, Madrid, 28007

  • Fundacion Jimenez Diaz

    Madrid, Madrid, 28040

  • Hospital Clinico San Carlos

    Madrid, Madrid, 28040

  • Hospital La Paz

    Madrid, Madrid, 28046

  • Hospital Regional de Malaga

    Málaga, Andalusia, 29010

  • Complejo Hospitalario de Pontevedra

    Pontevedra, Galicia, 36071

  • Hospital Universitario de Salamanca

    Salamanca, Castille and León, 37007

  • Hospital Nuestra Senora de la Candelaria

    Santa Cruz de Tenerife, Canary Islands, 38010

  • Hospital Virgen del Rocio

    Seville, Andalusia, 41013

  • Hospital Universitario Rio Hortega

    Valladolid, Castille and León, 47012

Other trials in Spain

About this study

Official title: A Multicentre Prospective Observational Study to Assess Health Related Quality of Life in Crohn's Disease Patients With Complex Perianal Fistula Before and After Treatment: the CALYPSO Study

The purpose of this study is to assess the impact of treatment (medical and/or surgical) on Health-related Quality of Life (HRQoL) in participants with Crohn's Disease (CD) and Complex Perianal Fistula (CPF), by the Quality of Life in patients with Anal Fistula Questionnaire (QoLAF-Q), at 12 months after treatment initiation in routine clinical practice.

Read the detailed description

This is a prospective follow-up post-authorization observational study of participants with CD and CPF. The study will provide real-world data on how CPF treatments in CD participants affect their HRQoL.

The study will enroll approximately 300 participants. All participants will be enrolled in one observational cohort.

This multi-center trial will be conducted in Spain. The study will collect data from a routine medical practice visits for CD participants with CPF and an application that will be designed ad hoc and will passively record participant's data. The overall duration of this study will be approximately 31 months. Participants will be followed up at Months 6 and 12 post-treatment.

Keywords
Drug Therapy
Medical subject headings
Crohn Disease, Inflammatory Bowel Diseases, Gastrointestinal Diseases, Intestinal Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT04102163
Study groupRoleWhat they receive
All ParticipantsParticipants diagnosed with CD and CPF from approximately 20 Spanish hospitals, who will initiate medical or surgical treatment for their CPF within the eligibility period from Sep 2020 to Sep 2021, will be observed prospectively for approximately 31 months.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants With Change From Baseline in QoLAF-Q Scores at Month 12 After Treatment Initiation for CPF

    QoLAF-Q evaluates quality of life (QoL) among participants with both simple and complex anal fistula (AF). It is composed of a total of 14 items with a Likert scale from 1 to 5 points. Its score range is the following: zero impact=14 points; limited impact=15 to 28 points; moderate impact=29 to 42 points; high impact=43 to 56 points; and very high impact=57 to 70 points.

    Measured: Baseline and Month 12

Secondary outcomes (22)
  1. Number of Participants With Change From Baseline in QoLAF-Q Scores at Month 6 After Treatment Initiation for CPF

    QoLAF-Q evaluates QoL among participants with both simple and complex AF. It is composed of a total of 14 items with a Likert scale from 1 to 5 points. Its score range is the following: zero impact=14 points; limited impact=15 to 28 points; moderate impact=29 to 42 points; high impact=43 to 56 points; and very high impact=57 to 70 points.

    Measured: Baseline and Month 6

  2. Percentage of Participants With Clinically Significant Change From Baseline in QoLAF-Q Score at Months 6 and 12 After Treatment for CPF

    QoLAF-Q evaluates QoL among participants with both simple and complex AF. It is composed of a total of 14 items with a Likert scale from 1 to 5 points. Its score range is the following: zero impact=14 points; limited impact=15 to 28 points; moderate impact=29 to 42 points; high impact=43 to 56 points; and very high impact=57 to 70 points.

    Measured: Baseline, Months 6 and 12

  3. Change From Baseline in EuroQoL-Five Dimensions, Five Levels (EQ-5D-5L) Scores at Months 6 and 12 After Treatment for CPF

    The EQ-5D- is a generic, self-reported measure of utility that consists of a five-item descriptive system and a visual analogue scale (EQ VAS). The descriptive system has two versions, namely the 3L and 5L, both involving five health dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). In the EQ-5D-5L that will be used, participants may choose from the following five response levels: no problems=1; slight problems=2; moderate problems=3; severe problems=4; and unable to/extreme problems=5. Higher values indicate worst health.

    Measured: Baseline, Months 6 and 12

  4. Change From Baseline in Faecal Incontinence Quality of Life Scale (FIQOL) Scores at Months 6 and 12 After Treatment for CPF

    FIQOL comprises of 29 items that cover four dimensions of perceived health: lifestyle (10 items), behavior (9 items), depression/ self-perception (7 items), and embarrassment (3 items). Each item has a range of 1 to 4, with 1 being the lowest value for the state of quality of life.

    Measured: Baseline, Months 6 and 12

  5. Change From Baseline in Perceived Stress Scale (PSS) Scores at Months 6 and 12 After Treatment for CPF

    The PSS assesses participant's perceived nonspecific stress in a given situation or a daily life situation. The overall score of the scale is measured on a 14-item scale (from 0 to 4 points). Each item is scored 0 (never) to 4 (very often). Total score is obtained by inverting the scores on items 4, 5, 6, 7, 9, 10 y 13 (as follows: 0=4, 1=3, 2=2, 3=1 y 4=0) and summing up the scores of the 14 items. Higher total scores indicate higher perceived stress.

    Measured: Baseline, Months 6 and 12

  6. Change From Baseline in International Index of Erectile Function (IIEF) Scores at Months 6 and 12 After Treatment for CPF

    The IIEF is a multi-dimensional, self-administered questionnaire to assess erectile dysfunction. A score of 0 to 5 is awarded to each of the 15 questions that examine the 4 main domains of male sexual function: Erectile Function (EF), Orgasmic Function (OF), Sexual Desire (SD) and Intercourse Satisfaction (IS). EF has five categories: 1-10(Severe Erectile Dysfunction), 11-16(Moderate dysfunction), 17-21(Mild to moderate dysfunction), 22-25(Mild dysfunction), 26-30 (No dysfunction). OF: sum of Questions (Q) 9 and Q10, each rated 0 (no sexual stimulation) to 5 (almost always/always). OF domain score range: 0 to 10; lower scores denoted lower OF. SD: sum of Q11 and Q12, each rated 1 (almost never or low/no sexual desire) to 5 (almost always or very high sexual desire). SD domain score range: 2 to 10;lower scores denoted lower SD. IS: sum of Q6, Q7, and Q8, each rated 0 (low/no satisfaction) to 5 (high satisfaction). IS domain score range: 0 to 15; lower scores denoted lower satisfaction.

    Measured: Baseline, Months 6 and 12

  7. Change From Baseline in Female Sexual Function Index (FSFI) Scores at Months 6 and 12 After Treatment for CPF

    The FSFI is a 19-item multidimensional self-report questionnaire for the assessment of female sexual function. It has five domains of sexual function, including: desire and subjective arousal, lubrication, orgasm, satisfaction, and pain/discomfort. FSFI is scored on a scale ranging from 1.2 to 6.0 (desire), 0 to 6.0 (arousal, lubrication, orgasm, and pain/discomfort) or 0.8 to 6.0 (satisfaction), with higher scores indicating better performance. The total score, falling in a possible range from 2.0 to 36.0, is obtained by adding the six domain scores together.

    Measured: Baseline, Months 6 and 12

  8. Number of Participants Based on Type of Treatment, Dose, Dose Frequency and Date of Initiation

    Measured: Baseline

  9. Number of Participants Based on Biological Data

    Biological data includes blood count, electrolytes, C-reactive protein (CRP), and fecal calprotectin.

    Measured: Baseline, Months 6 and 12

  10. Number of Participants With Comorbidities Based on Charlson Comorbidity Index

    The Charlson Comorbidity Index is a 19-item measure assessing comorbid conditions. The total possible score on the Charlson Comorbidity Index ranges from 0 to 37. If a condition is not present, the score for that condition is zero. The higher scores indicate greater comorbidity.

    Measured: Baseline

  11. Number of Participants With Comedications for Treatment of CD and Fistula

    Measured: Baseline

  12. Number of Participants With Target CPF

    Measured: Baseline

  13. Number of Participants With the Presence of new CPF at Months 6 and 12

    Measured: Months 6 and 12

  14. Montreal Classification Assessed at Baseline

    Montreal Classification includes age at diagnosis, disease location and disease behavior. Disease behavior was classified according to the following: B1 = non-stricturing, non-penetrating; B2 = structuring; B3 = penetrating; P = perianal disease modifier. The change in Montreal Classification is presented in three categories: no change, deterioration, and improvement. Deterioration defined as an increase in behavior index between 1 and 3, or development of perianal disease.

    Measured: Baseline

  15. Number of Participants With Clinical characteristics Based on Harvey Bradshaw Index (HBI)

    HBI score is used to measure the disease activity of CD. It consists of clinical parameters: general well-being (0-4, where higher score means lower well being), abdominal pain (0-3, higher score means more severe pain), number of liquid stools per day, abdominal mass (0-3, where higher score means presence of swelling in the abdomen), and complications (score 1 per item). Total score is the sum of individual parameters. The score ranges from a minimum score of 0 to no pre-specified maximum score as it depends on the number of liquid stools, where higher scores indicating more severe disease.

    Measured: Baseline, Months 6 and 12

  16. Number of Participants With Clinical Characteristics Based on Perianal Crohn´s Disease Activity Index (PDAI) or Fistula Drainage Assessment (FDA)

    The PDAI is a scoring system to evaluate the severity of perianal lesion associated with CD. It includes the following 5 items: (a) Discharge; (b) Pain; (c) Restriction of sexual activity; (d) Type of perianal disease; and (e) Degree of induration. Each item is graded on a 5-point scale ranging from no symptoms (score of 0) to severe symptoms (score of 4) and total range of score is from 0 to 20. Higher score means more severe disease.

    Measured: Baseline, Months 6 and 12

  17. Number of Occurrences of Treatment Switching or Dose Change

    Measured: Months 6 and 12

  18. Relation Between Participants QoLAF-Q Score and Clinical Variables

    A parametric test will be used to measure the degree of association between the QolAF score and clinical variable. QoLAF-Q evaluates QoL among participants with both simple and complex AF. It is composed of a total of 14 items with a Likert scale from 1 to 5 points. Its score range is the following: zero impact=14 points; limited impact=15 to 28 points; moderate impact=29 to 42 points; high impact=43 to 56 points; and very high impact=57 to 70 points.

    Measured: Baseline

  19. Number of Participants Based on Methods Used to Evaluate the Response to Different Treatments for CPF in Routine Clinical Practice

    Measured: Months 6 and 12

  20. Number of Participants Based on Effectiveness of Different Treatment Options for CPF Grouped According to Therapeutic Class

    The effectiveness of different treatment options for CPF grouped according to therapeutic class (medical treatment, surgery or both) will be defined as the absence of draining despite gentle finger compression.

    Measured: Months 6 and 12

  21. Health Care Resources Utilization (HCRU)

    HCRU includes emergency department and Intensive Care Units (ICU) visits; hospitalization (greater than or equal to (>=) 24 hours or related complications; number, type and reason for gastroenterology specialist or other specialty referral outpatient visits for management of complex perianal fistulas; surgeries or related complications; number of Magnetic Resonance Imaging (MRI) of the pelvis or transperineal, endoscopic ultrasound (EUS), and other non-surgical procedures performed to guide therapy, number of blood tests performed.

    Measured: Baseline, Months 6 and 12

  22. Correlation Between the Change in CD Participant's Scores in the QoLAF-Q, the EQ-5D-5L and Rapid Assessment Faecal Incontinence Score (RAFIS)

    Correlations between the scores obtained in the QoLAF-Q scale and the scores obtained in the RAFIS and EQ-5D-5L will be studied using Pearson correlation coefficients. QoLAF-Q evaluates QoL among participants with both simple and complex AF. It consists of a total of 14 items with a Likert scale from 1-5 points. Its score ranges:zero impact=14 points;limited impact=15 to 28 points; moderate impact=29 to 42 points;high impact=43 to 56 points;and very high impact=57 to 70 points. The EQ-5D- is a generic, self-reported measure of utility that consists of a 5-item descriptive system and EQ VAS. The descriptive system has 2 versions: 3L and 5L,both involving 5 health dimensions (mobility,self-care,usual activities, pain/discomfort and anxiety/depression). In the EQ-5D-5L that will be used, participants may choose from the following 5 response levels:no problems=1; slight problems=2;moderate problems=3; severe problems=4;and unable to/extreme problems=5.Higher values indicate worst health.

    Measured: Baseline, Months 6 and 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Sep 2019
  2. Study start26 Jan 2021
  3. Primary completion26 May 2021
  4. Study completion26 May 2021

Why it stopped: Business Decision; No Safety or Efficacy Concerns

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
19 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04102163
Sponsor's protocol ID
IBD-5008
Other IDs
U1111-1232-1975
Acronym
CALYPSO
Status last verified
Jul 2021
First submitted
23 Sep 2019
Last updated
27 Jul 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Questions about this trial

What is this clinical trial studying?

An observational study of Crohn Disease and Inflammatory Bowel Disease, run by Takeda at 20 sites in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 27 Jul 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 20 sites in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: Business Decision; No Safety or Efficacy Concerns). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants With Change From Baseline in QoLAF-Q Scores at Month 12 After Treatment Initiation for CPF (time frame: Baseline and Month 12). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jul 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in